Annual report pursuant to Section 13 and 15(d)

Nature of Business and Summary of Significant Accounting Policies (Details Narrative)

v3.21.1
Nature of Business and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
12 Months Ended
Dec. 20, 2019
Dec. 31, 2020
Dec. 31, 2019
Proceeds from debt and equity financing   $ 700,000  
Reverse stock split 1,000-for-1-reverse stock split    
Cash FDIC amount    
Provision for doubtful accounts   0 $ 0
Research and development expenses   $ 3,283 $ 153,126
Minimum [Member]      
Property plant and equipment, estimated useful lives   5 years  
Maximum [Member]      
Property plant and equipment, estimated useful lives   7 years  
Hanover Portfolio Acquisitions, Inc [Member]      
Acquisitions description   On January 22, 2014, Hanover Portfolio Acquisitions, Inc. (the "Company") received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company's Certificate of Incorporation to change the name of the Company from "Hanover Portfolio Acquisitions, Inc." to "Endonovo Therapeutics, Inc." The name change was affected pursuant to a Certificate of Amendment (the "Certificate of Amendment"), filed with the Secretary of State of Delaware on January 24, 2014.  
Common stock, voting rights   Common Stock representing in excess of 50% of the total issued and outstanding voting power